This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
Launching in 2022, its availability will be expanded to the global market
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
The move signals a major expansion milestone for the Swiss laboratory automation company
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
